Pilot Study Of The Effect Of Rifaximin On B-Cell Dysregulation In Cirrhosis
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Gastrointestinal, Hepatitis, Hepatitis, Hepatitis |
| Therapuetic Areas: | Gastroenterology, Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | 18 - 70 |
| Updated: | 3/27/2019 |
| Start Date: | August 2016 |
| End Date: | September 2019 |
Prospective Pilot Study of the Effect of Rifaximin on B-Cell Dysregulation in Cirrhosis Due to Chronic Hepatitis C Infection
Hepatitis C is the leading cause of chronic liver disease and cirrhosis in United States
veterans. Cirrhosis is associated with impaired antibody responses and increased risk of
bacterial infections. We have recently identified that cirrhosis is associated with
abnormalities of memory B-cells, cells that make antibodies and help protect against
bacterial infections. We have identified that chemicals associated with gut bacteria might
play a role in causing these B-cell abnormalities. It is well known that gut bacteria have
increased access to the blood in individuals with cirrhosis, a process called bacterial
translocation. We hypothesize that reducing bacteria counts in the gut by using
poorly-absorbed antibiotics (also known as selective gut decontamination) will partially
reverse losses of memory B-cells in cirrhosis by reducing bacterial translocation.
veterans. Cirrhosis is associated with impaired antibody responses and increased risk of
bacterial infections. We have recently identified that cirrhosis is associated with
abnormalities of memory B-cells, cells that make antibodies and help protect against
bacterial infections. We have identified that chemicals associated with gut bacteria might
play a role in causing these B-cell abnormalities. It is well known that gut bacteria have
increased access to the blood in individuals with cirrhosis, a process called bacterial
translocation. We hypothesize that reducing bacteria counts in the gut by using
poorly-absorbed antibiotics (also known as selective gut decontamination) will partially
reverse losses of memory B-cells in cirrhosis by reducing bacterial translocation.
We intend to enroll 18 patients with cirrhosis who do not have hepatic encephalopathy to
prospectively evaluate the impact of rifaximin on B-cell phenotype and function. We plan to
employ a randomized, double-masked, prospective crossover design to minimize bias. Subjects
will be randomized to receive either rifaximin SSD 80mg or a matched placebo once daily for
12 weeks then crossed over to opposite therapy for 12 weeks. Serum and lymphocytes will be
collected at baseline and every 4 weeks for in vitro assessment markers of gut microbial
translocation and B-cell assays. Stool will be collected at baseline and every 12 weeks for
future evaluation of changes of the gut microbiome.
prospectively evaluate the impact of rifaximin on B-cell phenotype and function. We plan to
employ a randomized, double-masked, prospective crossover design to minimize bias. Subjects
will be randomized to receive either rifaximin SSD 80mg or a matched placebo once daily for
12 weeks then crossed over to opposite therapy for 12 weeks. Serum and lymphocytes will be
collected at baseline and every 4 weeks for in vitro assessment markers of gut microbial
translocation and B-cell assays. Stool will be collected at baseline and every 12 weeks for
future evaluation of changes of the gut microbiome.
Inclusion Criteria:
- Current or prior chronic Hepatitis C infection as documented by detectable HCV RNA in
prior 5 years
- Child-Turcotte-Pugh stage A5-B8. Cirrhosis diagnosis may be based on either
histological criteria (an previous liver biopsy showing F4/4 or F5-6/6 fibrosis) or
clinical criteria (nodular liver on abdominal imaging, splenomegaly, thrombocytopenia,
spider telangiectasias, palmar erythema, ascites, varices).
- Platelet count < 175,000/ul
- Subject capable of giving informed consent
Exclusion Criteria:
- Active alcohol use > 20g/d
- Current or planned (within following 6 months) antiviral therapy for hepatitis C
- HIV co-infection
- Diagnosis of overt hepatic encephalopathy
- Current lactulose use
- Exposure to rifaximin, rifampin or rifabutin within 12 months
- History of C. difficile colitis
- History of adverse drug reaction or sensitivity to rifaximin, rifampin or rifabutin or
any inactive components of rifaximin
- Pregnancy
- Anemia with hemoglobin < 10g/dl or hematocrit < 30%
- Chronic kidney disease with creatinine > 2.1mg/dl
- Total bilirubin > 3.0g/dl
- Active non-hepatic medical conditions such as congestive heart failure, chronic lung
disease requiring oxygen, coronary artery disease with unstable angina
- Requirement for chronic immunosuppressive therapy such as corticosteroids,
cyclophosphamide, azathioprine, TNF-alpha antagonists
- Chronic autoimmune diseases such as systemic lupus erythematosus and rheumatoid
arthritis
- Post-liver transplantation status or anticipated liver transplantation within 6
months.
- Systemic antimicrobial exposure within 30 days of planned Visit 1
We found this trial at
1
site
Philadelphia, Pennsylvania 19104
Principal Investigator: David E Kaplan, MD MSc
Phone: 215-823-5800
Click here to add this to my saved trials
